Cited 0 times in
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, HA | - |
dc.contributor.author | Lee, JW | - |
dc.contributor.author | Nam, SJ | - |
dc.contributor.author | Park, BW | - |
dc.contributor.author | Im, SA | - |
dc.contributor.author | Lee, ES | - |
dc.contributor.author | Jung, YS | - |
dc.contributor.author | Yoon, JH | - |
dc.contributor.author | Kang, SS | - |
dc.contributor.author | Lee, SJ | - |
dc.contributor.author | Park, KH | - |
dc.contributor.author | Jeong, J | - |
dc.contributor.author | Cho, SH | - |
dc.contributor.author | Kim, SY | - |
dc.contributor.author | Kim, LS | - |
dc.contributor.author | Moon, BI | - |
dc.contributor.author | Lee, MH | - |
dc.contributor.author | Kim, TH | - |
dc.contributor.author | Park, C | - |
dc.contributor.author | Jung, SH | - |
dc.contributor.author | Gwak, G | - |
dc.contributor.author | Kim, J | - |
dc.contributor.author | Kang, SH | - |
dc.contributor.author | Jin, YW | - |
dc.contributor.author | Kim, HJ | - |
dc.contributor.author | Han, SH | - |
dc.contributor.author | Han, W | - |
dc.contributor.author | Hur, MH | - |
dc.contributor.author | Noh, WC | - |
dc.contributor.author | Korean Breast Cancer Study Group | - |
dc.date.accessioned | 2022-11-11T04:09:30Z | - |
dc.date.available | 2022-11-11T04:09:30Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/22526 | - |
dc.description.abstract | PURPOSE: The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy. PATIENTS AND METHODS: We enrolled 1,483 premenopausal women (age | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antineoplastic Agents, Hormonal | - |
dc.subject.MESH | Breast Neoplasms | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follicle Stimulating Hormone | - |
dc.subject.MESH | Gonadotropin-Releasing Hormone | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Ovary | - |
dc.subject.MESH | Premenopause | - |
dc.subject.MESH | Tamoxifen | - |
dc.title | Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial | - |
dc.type | Article | - |
dc.identifier.pmid | 31518174 | - |
dc.contributor.affiliatedAuthor | Jung, YS | - |
dc.contributor.affiliatedAuthor | Han, SH | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1200/JCO.19.00126 | - |
dc.citation.title | Journal of clinical oncology | - |
dc.citation.volume | 38 | - |
dc.citation.number | 5 | - |
dc.citation.date | 2020 | - |
dc.citation.startPage | 434 | - |
dc.citation.endPage | 443 | - |
dc.identifier.bibliographicCitation | Journal of clinical oncology, 38(5). : 434-443, 2020 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.relation.journalid | J00732183X | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.